Two Korean Pharmas Vie For Wins In High-Need Gout Space
Promising Data Support Move Into Phase III
Executive Summary
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.
You may also be interested in...
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.
What's Keeping Korea From Adopting Decentralized Clinical Trials?
The current status of decentralized clinical trials in Korea and the country’s efforts to boost activity in this area were discussed at the recent Bio Korea meeting, with cultural and medical practices, along with technological and medical literacy, among the areas seen as affecting broader adoption of the various elements of the approach.